华健未来-B(06132)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06132 华健未来-B

已收盘 07-06 16:08:30

34.000

-1.840

-5.13%

最高36.200	最低32.380	成交量26.42万
今开35.840	昨收35.840	日振幅10.66%
总市值25.02亿	流通市值25.02亿	总股本7,360万
成交额887.69万	换手率0.36%	流通股本7,360万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06132","market":"HK","secType":"STK","nameCN":"华健未来-B","latestPrice":34,"timestamp":1783325310664,"preClose":35.84,"halted":0,"volume":264200,"delay":0,"changeRate":-0.0513392857142858,"floatShares":73599600,"shares":73599605,"eps":0,"marketStatus":"已收盘","change":-1.84,"latestTime":"07-06 16:08:30","open":35.84,"high":36.2,"low":32.38,"amount":8876906,"amplitude":0.106585,"askPrice":34,"askSize":1300,"bidPrice":33.9,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-2.032,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783387800000},"marketStatusCode":5,"adr":0,"listingDate":1782144000000,"exchange":"SEHK","adjPreClose":35.84,"openAndCloseTimeList":[[1783301400000,1783310400000],[1783314000000,1783324800000]],"volumeRatio":0.795927,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06132","defaultTab":"news","newsList":[{"id":"1119941497","title":"异动解读｜华健未来-B盘中下跌9.37%，上市以来持续承压累计跌超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119941497","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119941497?lang=zh_cn&edition=full","pubTime":"2026-07-03 10:16","pubTimestamp":1783045016,"startTime":"0","endTime":"0","summary":"7月3日，华健未来-B盘中下跌9.37%，报37.6港元/股，成交额70.27万港元。消息面上，公司于6月23日以81.8港元/股发行价登陆港交所，上市首日即大幅破发收跌56.89%，此后股价持续低位震荡。公司作为港交所18A章上市的临床阶段生物科技公司，目前尚无产品获批商业销售，核心产品HJ787、HJ178、HJ891均处于临床阶段，各赛道竞争激烈。华健未来由多位博士共同创立，主要从事针对肿瘤、自身免疫系统疾病和代谢系统疾病创新药物的研发和生产。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129586220","title":"异动解读｜华健未来-B盘中上涨8.75%，报39.02港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1129586220","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129586220?lang=zh_cn&edition=full","pubTime":"2026-07-02 13:31","pubTimestamp":1782970315,"startTime":"0","endTime":"0","summary":"7月2日，华健未来-B盘中上涨8.75%，报39.02港元/股，成交额539.2万港元。华健未来由多位博士共同创立，主要从事针对肿瘤、自身免疫系统疾病和代谢系统疾病创新药物的研发和生产。公司于6月23日以81.8港元/股发行价登陆港交所，作为18A章上市的临床阶段生物科技公司，目前尚无产品获批商业销售，核心产品HJ787、HJ178、HJ891均处于临床阶段。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145308583","title":"异动解读｜华健未来-B盘中下跌8.07%，上市以来持续承压累计跌超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145308583","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145308583?lang=zh_cn&edition=full","pubTime":"2026-06-30 09:47","pubTimestamp":1782784048,"startTime":"0","endTime":"0","summary":"6月30日，华健未来-B盘中下跌8.07%，报37.3港元/股，成交额175.19万港元。消息面上，公司于6月23日以81.8港元/股发行价登陆港交所，上市首日即大幅破发收跌56.89%，此后股价持续低位震荡。公司作为港交所18A章上市的临床阶段生物科技公司，目前尚无产品获批商业销售，核心产品HJ787、HJ178、HJ891均处于临床阶段，各赛道竞争激烈。华健未来由多位博士共同创立，主要从事针对肿瘤、自身免疫系统疾病和代谢系统疾病创新药物的研发和生产。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187245908","title":"异动解读｜华健未来-B盘中下跌8.12%，上市以来持续承压累计跌超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1187245908","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187245908?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:46","pubTimestamp":1782701172,"startTime":"0","endTime":"0","summary":"6月29日，华健未来-B盘中下跌8.12%，报40.5港元/股，成交额444.59万港元。消息面上，公司于6月23日以81.8港元/股发行价登陆港交所，上市首日即大幅破发收跌56.89%，此后股价持续低位震荡。公司作为港交所18A章上市的临床阶段生物科技公司，目前尚无产品获批商业销售，核心产品HJ787、HJ178、HJ891均处于临床阶段，且各赛道竞争激烈。叠加近期恒指持续走弱，市场资金偏好转向AI等高成长板块，未盈利生物科技标的遭遇系统性抛压，股价延续调整态势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154895339","title":"异动解读｜华健未来-B盘中上涨8.96%，报38.9港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154895339","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154895339?lang=zh_cn&edition=full","pubTime":"2026-06-25 10:11","pubTimestamp":1782353475,"startTime":"0","endTime":"0","summary":"6月25日，华健未来-B盘中上涨8.96%，报38.9港元/股，成交额674.63万港元。华健未来由多位博士共同创立，主要从事针对肿瘤、自身免疫系统疾病和代谢系统疾病创新药物的研发和生产。公司于6月23日以81.8港元/股发行价登陆港交所，上市首日收报35.26港元，跌幅达56.89%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645865226","title":"【特约大V】邓声兴：大市沽压气氛浓厚，港股料续寻底","url":"https://stock-news.laohu8.com/highlight/detail?id=2645865226","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645865226?lang=zh_cn&edition=full","pubTime":"2026-06-24 10:19","pubTimestamp":1782267549,"startTime":"0","endTime":"0","summary":"国指跌155点或1.96%，报7759点。大市沽压气氛浓厚，港股料续寻底。收入增长主要由财富管理业务费用及其他收益强劲增长所驱动，非利息收入达78.72亿美元，按年增长10.2%；净利息收入112.5亿美元，按年增长6.2%，管理层更上调全年净利息收入指引至不低于460亿美元。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/ZTVmMTM1MjM4NjExMzI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZTVmMTM1MjM4NjExMzI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984370","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2449936058.SGD","BK1592","LU0708995583.HKD","IE0008369823.USD","LU0516422952.EUR","LU2213484517.USD","LU0918141705.HKD","LU0516422366.SGD","LU0359202008.SGD","LU0516422440.USD","LU0359201885.HKD","LU0634319403.HKD","SG9999004311.SGD","BK1601","06132","LU0052750758.USD","LU1880383366.USD","03143","LU1880383440.USD","LU0348735423.USD","HSBA.UK","LU1481107354.HKD","HSHD.SI","BK1610","00005","06067","BK1572","BK4588","BK1110","LU1105468828.SGD","LU2187417386.USD","LU2929501877.USD","LU0348816934.USD","LU0516423174.USD","HSBC","LU0417516738.SGD","LU0348814723.USD","LU0918141887.USD","03993","BK4585","LU0359201612.USD","BK1594","LU1023057109.AUD","LU2351347302.SGD","LU1282648689.USD","LU0797268264.HKD","BK1190","LU0320764599.SGD","VXUS","LU0516423091.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126263566","title":"异动解读｜华健未来-B盘中下跌12.78%，上市首日破发跌穿招股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1126263566","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126263566?lang=zh_cn&edition=full","pubTime":"2026-06-23 09:34","pubTimestamp":1782178465,"startTime":"0","endTime":"0","summary":"6月23日，华健未来-B上市首日盘中下跌12.78%，报65.05港元，成交额4.13亿港元，大幅跌破招股价81.80港元。消息面上，公司虽获香港公开发售超购2007.6倍，暗盘一度涨约49%-53%，但正式挂牌后股价即告破发。本次全球发售1360万股H股，每股定价81.80港元，净筹约10.19亿港元。华健未来由多位博士共同创立，主要从事针对肿瘤、自身免疫系统疾病和代谢系统疾病创新药物的研发和生产。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146758161","title":"异动解读 | 华健未来-B上市首日盘中大跌5.01%，市场担忧其尚未盈利且财务亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=1146758161","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146758161?lang=zh_cn&edition=full","pubTime":"2026-06-23 09:33","pubTimestamp":1782178436,"startTime":"0","endTime":"0","summary":"华健未来-B今日在港股市场上市首日盘中出现大幅下挫，股价一度下跌5.01%，引起了投资者的广泛关注。消息面上，华健未来-B作为一家临床阶段的生物科技公司，目前尚无任何产品获得批准进行商业销售，也未从产品销售中产生任何收益。此次IPO募集资金净额约10.19亿港元，计划主要用于管线产品的临床研究及开发。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645790009","title":"新股首日 | 华健未来-B(06132)首挂上市 早盘平开 公司拥有三个核心产品但尚未获批销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2645790009","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645790009?lang=zh_cn&edition=full","pubTime":"2026-06-23 09:23","pubTimestamp":1782177810,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华健未来-B首挂上市，公告显示，每股定价81.8港元，共发行1360万股股份，每手100股，所得款项净额约10.19亿港元。招股书显示，华健未来为一家于2017年由致力研发自身免疫、代谢及肿瘤学疾病疗法的行业专家团队创立的临床阶段生物科技公司。迄今，公司并无产品获批准进行商业销售，亦无自产品销售产生任何收益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457306.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06132","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187304218","title":"新股定价 | 华健未来-B发售价为每股81.8港元，公开发售超购2006.6倍认购，一手中签率2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1187304218","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187304218?lang=zh_cn&edition=full","pubTime":"2026-06-23 07:44","pubTimestamp":1782171863,"startTime":"0","endTime":"0","summary":" $华健未来-B(06132)$06132)公布配发结果，公司全球发售1360万股H股，香港公开发售占10%，国际发售占90%。最终发售价为每股81.8港元，全球发售净筹约10.19亿港元。每手100股，一手中签率2%，预期H股将于今日(6月23日)上午九时正(香港时间)于联交所开始买卖。其中，香港公开发售获2007.6倍认购，国际发售获7倍认购。","market":"us","thumbnail":"https://community-static.tradeup.com/news/abc720622944b8f4378e8e1c01e3dbdd","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/abc720622944b8f4378e8e1c01e3dbdd"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"3430ee0e05254278b5a3da84a7b77b4c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645786910","title":"华健未来-B(06132.HK)香港公开发售获2007.60倍认购 6月23日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2645786910","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645786910?lang=zh_cn&edition=full","pubTime":"2026-06-22 21:57","pubTimestamp":1782136625,"startTime":"0","endTime":"0","summary":"格隆汇6月22日丨华健未来-B(06132.HK)公告，公司全球发售13,600,000股H股，每股H股81.80港元，所得款项净额10.19亿港元。香港公开发售股份数目占全球发售股份数目10.00%，获认购2,007.60倍；国际发售股份数目占全球发售股份90.00%，获认购倍7.00倍。\r\n\r\n　　假设全球发售于2026年6月23日(星期二)上午八时正(香港时间)或之前成为无条件，预期H股将于2026年6月23日(星期二)上午九时正(香港时间)于联交所开始买卖。H股将以每手100股H股为单位买卖，H股股份代号将为6132。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260622/32286240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["06132","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165839576","title":"华健未来-B香港公开发售最终发售股份数目为140万股H股 每股发售价81.80港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1165839576","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165839576?lang=zh_cn&edition=full","pubTime":"2026-06-22 21:34","pubTimestamp":1782135275,"startTime":"0","endTime":"0","summary":"华健未来-B（HJ SCIENCE-B）公布其香港公开发售的最终股份分配详情。根据公告，本次公开发售的最终发售股份数目确定为140万股H股，每股发售价为81.80港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645476800","title":"新股暗盘 | 华健未来-B(06132)暗盘盘初涨近53% 每手赚4320港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2645476800","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645476800?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:20","pubTimestamp":1782116429,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华健未来-B(06132)将于6月23日(周二)在香港挂牌。截至发稿，暗盘交易显示报价125港元，较招股价81.80港元上涨52.81%，每手100股，不计手续费，每手赚4320港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456864.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06132","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126747898","title":"老虎暗盘 | 华健未来暗盘大升49%，一手账面赚超4000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1126747898","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126747898?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:19","pubTimestamp":1782116352,"startTime":"0","endTime":"0","summary":"华健未来暗盘大升49%，一手账面赚超4000港元。华健未来于6月12日至17日招股，计划发行1360万股H股，一于香港作公开发售，发售价每股81.8港元，集资11.1亿港元，每手100股，一手入场费8262.5港元。中信証券为独家保荐人。","market":"hk","thumbnail":"https://static.tigerbbs.com/3ce4524f3159771d39966dbd4e93487d","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3ce4524f3159771d39966dbd4e93487d"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"3430ee0e05254278b5a3da84a7b77b4c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183744420","title":"一周前瞻 | 美光财报重磅来袭；英伟达股东大会聚焦AI产能；美国PCE数据揭晓；中科闻歌、芯碁微装等上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1183744420","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183744420?lang=zh_cn&edition=full","pubTime":"2026-06-22 07:10","pubTimestamp":1782083431,"startTime":"0","endTime":"0","summary":"市场关注要点：HBM3E产能扩张进度AI数据中心DRAM需求展望传统PC/手机市场复苏情况对英伟达Blackwell平台的供货情况英伟达股东大会：AI产能规划受瞩目英伟达将于周三举行年度股东大会，黄仁勋预计将就以下议题向股东更新：Blackwell架构产能爬坡进展Vera CPU架构与下一代产品路线图AI基础设施长期需求展望美国PCE数据：美联储降息预期关键指标美国5月个人消费支出物价指数将于周四公布，这是美联储最青睐的通胀指标。","market":"us","thumbnail":"https://static.tigerbbs.com/f1ba9d7118bf176c3c40e42b5a99126a","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/f1ba9d7118bf176c3c40e42b5a99126a"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMAX","07788","MMAX","SMAX","ANV","NVII","NVDB","NVDX","SDS","01688","SSO","01956","NVD","IVV","DIPS","NVDY","NVDO","NVDG","DDM","06106","07388","NVDW","NVDD","NVDL","NVDU","NVDS","VOO","06067","SDOW",".DJI",".IXIC","06228","MUD","NVDQ","SPXS","NVYY","SPY","DOG","SPYM","DIA","09630","UDOW","MUU","03661","SH","06132","SPYU","SPYQ","01392","SPXL","UPRO","HIBL","MU","MULL","DXD","SPDN","SPUU","NVDA",".SPX","SPXU","SPYH","YSPY","02272"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2644713107","title":"新股消息 | 华健未来-B(06132)招股结束 孖展认购额录得1298亿港元 超购1166倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2644713107","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644713107?lang=zh_cn&edition=full","pubTime":"2026-06-17 14:23","pubTimestamp":1781677402,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，生物科技公司华健未来-B于2026年6月12日至6月17日招股，最新已结束招股。根据市场消息，华健未来已获券商借出约1298亿港元孖展，以公开发售集资额1.1亿港元计，超购1166倍。华健未来拟全球发售1360万股H股，其中，香港发售占10%，国际发售占90%，另有超额配股权15%。每股发售价81.80港元，每手100股，一手入场费8262.5港元，集资11.1亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06132","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643224753","title":"【IPO速递】宁德、高瓴加持！“钴王”旗下华创新材收入暴增却造血艰难","url":"https://stock-news.laohu8.com/highlight/detail?id=2643224753","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643224753?lang=zh_cn&edition=full","pubTime":"2026-06-15 16:46","pubTimestamp":1781513160,"startTime":"0","endTime":"0","summary":"华创新材的亮点与隐忧泾渭分明。2023至2025年，华创新材收入从43.62亿元增至86.30亿元，两年近乎翻倍，增长势头迅猛。比利润更严峻的是现金流问题，2023至2025年，华创新材的经营现金流处于持续净流出状态，2025年净流出高达38.22亿元，收入账面亮眼，主业却持续“失血”。此外，华创新材为典型家族控制企业，实控人为陈雪华夫妇。二人通过控股股东华友控股直接持股58.17%，叠加关联持股平台铜陵创安汇等，合计掌控公司61.72%的股权，公司控制权高度集中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s/C1ZkEXoEbT3F7QJmw2iDkQ","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU0359201612.USD","LU1934453819.USD","06132","LU1807302812.USD","LU1808992512.USD","300750","LU0359201885.HKD","SGXZ49509284.SGD","BK0077","LU0469268626.HKD","SGXZ81163826.USD","BK0233","BK1610","LU1152091168.USD","LU0067412154.USD","BK0224","LU0359202008.SGD","LU1960683339.HKD","BK0201","BK0155","06067","LU1979443071.USD","03750","BK1116","BK0132","603799","03677","BK0182","LU1993786604.SGD","LU1023057109.AUD","BK0070","LU0880133367.SGD","BK0188","EVS.SI","LU1781817850.SGD","BK0196","LU1580142542.USD","300014","LU1152091754.HKD","LU1008478684.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149230137","title":"华健未来（成都）科技股份有限公司首发13,600,000股H股，发售价每股81.80港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1149230137","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149230137?lang=zh_cn&edition=full","pubTime":"2026-06-12 07:30","pubTimestamp":1781220652,"startTime":"0","endTime":"0","summary":"华健未来（成都）科技股份有限公司成立于2017年，主要从事自身免疫、代谢和肿瘤等领域创新疗法的研究与开发，现有核心产品管线包括HJ787、HJ178、HJ891等，另有HJ356、HJ093、HJ198、HJ086等多款临床前候选药物。截至2024年12月31日止年度，收入约为人民币1,800千元，研发开支约为人民币74,973千元，年内亏损及全面亏损总额约为人民币202,317千元。公司本次全球发售总数为13,600,000股H股，发售价为每股81.80港元，香港公开发售部分为1,360,000股，国际配售部分为12,240,000股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"华健未来（成都）科技股份有限公司首发13,600,000股H股，发售价每股81.80港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06132"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.hj3h.com","stockEarnings":[{"period":"1week","weight":-0.1869},{"period":"1month","weight":-0.5619},{"period":"ytd","weight":-0.5619}],"compareEarnings":[{"period":"1week","weight":0.0299},{"period":"1month","weight":-0.0891},{"period":"3month","weight":-0.0703},{"period":"6month","weight":-0.1135},{"period":"1year","weight":-0.0299},{"period":"ytd","weight":-0.089}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"华健未来由多位博士共同创立,主要从事针对肿瘤,自身免疫系统疾病和代谢系统疾病创新药物的研发和生产","exchange":"SEHK","name":"华健未来-B","nameEN":"HJ SCIENCE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华健未来-B(06132)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华健未来-B(06132)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华健未来-B,06132,华健未来-B股票,华健未来-B股票老虎,华健未来-B股票老虎国际,华健未来-B行情,华健未来-B股票行情,华健未来-B股价,华健未来-B股市,华健未来-B股票价格,华健未来-B股票交易,华健未来-B股票购买,华健未来-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华健未来-B(06132)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华健未来-B(06132)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}